Latest filing published 23 Oct 2024 for Inhibikase Therapeutics, Inc., €184k.
Filing timeline
BuySaleInsider track record
Closed purchases
Not enough history yet: 1 closed purchase, at least 2 are needed.
Purchases by company
Since each purchase
- -38.9%Entry US$2.52 · Close at T+365 US$1.54
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Arvind Kush: trading record in brief
Arvind Kush has filed trades across 2 companies (mainly through SEC (Form 4)), most often in Inhibikase Therapeutics, Inc. and RayzeBio, Inc. We count 2 filings; the first trade dates from 26 February 2024 and the latest from 21 October 2024.
No open-market sale appears; the market trades are 1 purchase worth €184k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay.
The newest entry dates from 23 October 2024: an open-market purchase of €184k, in Inhibikase Therapeutics, Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Arvind Kush
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 145,000 shares@ US$1.37100.0% of flowCommon StockSEC:0000950170-24-116783:0Canonical exit: 19 Jan 2025 (T+90)
- 78,433 shares@ US$62.50100.0% of flowCommon StockSEC:0001415889-24-005502:0
2 of 2 declarations